Methods for treating peripheral nerve damage
VEGF-B, as well as a combination of VEGF-B and VEGF-A, mediates peripheral nerve repair. Methods to treat damage to the peripheral nervous system are described.
1. A method for treating peripheral nerve damage in an eye of a subject, comprising:
administering VEGF-B to the subject by topical application to the eye having the nerve damage in an amount effective to treat the peripheral nerve damage by stimulating nerve growth at a location of the nerve damage.
2. The method according to claim 1 , wherein the VEGF-B is administered to the subject in combination with VEGF-A.
3. The method according to claim 1 , wherein the VEGF-B is administered as a protein.
4. The method according to claim 2 , wherein the VEGF-B and the VEGF-A are administered as proteins.
5. The method according to claim 1 , wherein the VEGF-B is administered to the subject in a pharmaceutical composition by topical application at a location of the nerve damage.
6. The method according to claim 1 , further comprising, after the administering of the VEGF-B, a second topical administration to the eye of a subject of a second effective amount of VEGF-B or of VEGF-A.
7. The method according to claim 2 , further comprising, after the administering of the VEGF-B, a second topical administration to the eye of a subject of a second effective amount of VEGF-B or of VEGF-A.
8. The method according to claim 7 , wherein the second administration is of a second effective amount of VEGF-B.
9. The method according to claim 8 , wherein the second administration is after a time of from 1 or more minutes to 2 days after the first administration of VEGF-B.
10. The method according to claim 1 , wherein the peripheral nerve damage is neuritis.
11. The method according to claim 1 , wherein the VEGF-B is administered as a nucleic acid encoding VEGF-B protein.
12. A method for treating ocular nerve damage in an eye of a subject, comprising:
administering an effective amount of VEGF-B to a subject by topical administration to the eye suffering from the ocular nerve damage.
13. The method according to claim 12 , wherein the ocular nerve damage is a result of trauma caused by an accident or surgery.
14. The method according to claim 12 , wherein the ocular nerve damage is in the cornea.
15. The method according to claim 12 , wherein the ocular damage is neuritis.
16. The method according to claim 12 , comprising administering the VEGF-B to the subject in combination with an effective amount of VEGF-A.
17. The method according to claim 16 , further comprising, after the administering of the VEGF-B in combination with VEGF-A, a second topical administration to the eye of a subject of a second effective amount of VEGF-B or of VEGF-A.
18. The method according to claim 17 , wherein the second administration is after a time of from 1 or more minutes to 2 days after the first administration of VEGF-B.
19. The method according to claim 17 , wherein the second administration is of a second effective amount of VEGF-B.
20. The method according to claim 17 , wherein the second administration is of a second effective amount of VEGF-A.
21. The method according to claim 12 , wherein the VEGF-B is administered as a nucleic acid encoding VEGF-B protein.